Evolva and Valent BioSciences to co-develop agricultural bioactives
Evolva and Valent BioSciences Corporation (VBC), a subsidiary of Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are not being identified at this time.
The collaboration will start by developing yeast strains that make the desired ingredients. Evolva has the primary responsibility for this phase while VBC will be responsible for commercialisation. The companies will work together on scale-up and manufacturing. The first products from the collaboration are expected to be launched in 4-5 years.
Total spending on the project during the next five years is estimated at CHF 12-14 million. Evolva and VBC have agreed to split equally both the R&D costs and profits from active ingredient sales.
Other news from the department career
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
